Talking to Your Care Team about Your Sexual Orientation and Gender Identity
While it may be an uncomfortable topic to bring up, sharing your sexual orientation and gender identity with your cancer…
Blog - Melanoma360
10/11/2022
Talking to Your Care Team about Your Sexual Orientation and Gender Identity
While it may be an uncomfortable topic to bring up, sharing your sexual orientation and gender identity with your cancer…
|
09/30/2022
Giving immunotherapy before targeted therapy improves survival in patients with advanced melanoma
(Source:Georgetown University Medical Center) Originally published Sep 27, 2022, Medical Life Sciences Giving immunotherapy before targeted therapy improves survival in…
|
09/29/2022
Val Guild Honored at 2022 ASCO Annual Conference
by Alicia Rowell, Vice President Saturday, June 4 was a special evening. In Chicago that week many of the nation’s…
|
09/27/2022
President’s Letter | September 2022
From the Desk of Samantha Guild Leaves are falling, pumpkins are out, football is on TV, and the kids are…
|
09/27/2022
AIM Welcomes Ann Garst Taylor as New Director of Community Engagement
By Mara Klecker Ann Garst Taylor, AIM at Melanoma’s new Director of Community Engagement, has nearly 30 years of volunteer…
|
09/27/2022
AIM Welcomes Michelle Bessett as New Director of National Walks & Events
by Mara Klecker Michelle Bessett has always loved working with and helping other people. As AIM at Melanoma’s new Director…
|
09/16/2022
Bristol Myers Squibb Receives European Commission Approval for LAG-3-Blocking Antibody Combination, Opdualag , for the Treatment of Unresectable or Metastatic Melanoma with Tumor Cell PD-L1 Expression < 1%
(NEWS PROVIDED BY Bristol Myers Squibb, September 16, 2022, ) Opdualag is a first-in-class, fixed-dose dual immunotherapy combination treatment of the…
|
09/13/2022
Spirituality and Cancer Care With Michael Eselun, BCC
When faced with a cancer diagnosis, some patients rely on their spirituality to cope and find meaning behind the experience.…
|
09/13/2022
ESMO: TIL therapy improves on Yervoy in melanoma trial
(NEWS PROVIDED BY Pharmaphorum, September 11, 2022, Phil Taylor) A personalised cell therapy based on tumour-infiltrating lymphocyte (TIL) cells has…
|
09/12/2022
Regeneron Reports Fianlimab plus Libtayo Showed Above 60% Response Rate in Patients with Advanced Melanoma Naïve to PD-1 or PD-L1 Inhibitors
(NEWS PROVIDED BY Regeneron Pharmaceuticals, Inc. Sep 12, 2022, 02:30 ET) Positive clinical data presented in a mini-oral session at ESMO…
|
Recent Posts
Nov. 22, 2024
Replimune Receives Breakthrough Therapy Designation for RP1 and Submits BLA to FDA
Nov. 22, 2024
Meaning-Centered Psychotherapy for Cancer Patients
Nov. 05, 2024
Crafting Hope: Chris Krizek’s Journey from Cancer Patient to AIM Fundraiser with Wine Cork Creations
Nov. 04, 2024
Book Suggestions for Caregivers
Oct. 28, 2024